the Company intends to use funds raised from the October Placement towards:
(i) accelerating the Company’s entry into the Australian medical cannabis
market;
(ii) funding the costs of the October Placement; and
(iii) funding the working capital expenditure of the Company and its subsidiaries
in Europe, Canada and Israel.
The $2m wasn't just for the Aussie market.
Ann: Appendix 4C - quarterly, page-69
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
